Drug intelligence / Profile preview

etanautine

Development stage: Unknown
Modality: Small Molecules

Overview

Etanautine is a legacy **small-molecule antiparkinsonian anticholinergic**. It is the 1:1 salt of diphenhydramine and acefylline, also called diphenhydramine monoacefyllinate. Its therapeutic pharmacology is principally attributed to diphenhydramine-associated central antimuscarinic and histamine H1 receptor-antagonist activity; the acefylline component is a xanthine derivative reported to counterbalance diphenhydramine-related sedation. Etanautine is assigned WHO ATC code N04AB01 among anticholinergic antiparkinsonian agents. ([pubchem.ncbi.nlm.nih.gov](https://pubchem.ncbi.nlm.nih.gov/compound/Etanautine))

Other names: diphenhydramine monoacefyllinateetanautine

Targets

ADOR (Adenosine receptors)mAChR (Muscarinic acetylcholine receptors)

Beyond the preview

Go deeper on etanautine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on etanautine.

Explore the full profile